|
Delayed
London S.E.
18:35:20 28/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.400 GBX | +5.66% |
|
-5.41% | -44.00% |
| 09-25 | WINNERS & LOSERS: Bango "cautiously optimistic" as earnings grow | AN |
| 09-16 | EARNINGS: Proteome Sciences "confident" for full year as loss narrows | AN |
Company Valuation: Proteome Sciences plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 11.42 | 15.13 | 10.33 | 13.37 | 10.04 | 7.38 |
| Change | - | 32.43% | -31.71% | 29.43% | -24.94% | -26.47% |
| Enterprise Value (EV) 1 | 20.25 | 24.43 | 18.25 | 24.82 | 23.43 | 22.37 |
| Change | - | 20.62% | -25.28% | 35.98% | -5.6% | -4.53% |
| P/E | 38.7x | 258x | 8.14x | -5.46x | -2.95x | -2.4x |
| PBR | -3.4x | -5.45x | -12.3x | -4.36x | -1.54x | -0.77x |
| PEG | - | -3.2x | 0x | 0x | -0.1x | 0.24x |
| Capitalization / Revenue | 2.4x | 2.95x | 1.33x | 2.66x | 2.05x | 1.96x |
| EV / Revenue | 4.26x | 4.76x | 2.35x | 4.94x | 4.79x | 5.96x |
| EV / EBITDA | 34.9x | 54x | 9.95x | -16.6x | -10.6x | -9x |
| EV / EBIT | 36.9x | 59.3x | 10.6x | -15.3x | -9.96x | -8.39x |
| EV / FCF | 19.6x | 76.9x | 25.2x | -43.1x | -42.4x | -58.7x |
| FCF Yield | 5.11% | 1.3% | 3.97% | -2.32% | -2.36% | -1.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.000999 | 0.000199 | 0.004299 | -0.008299 | -0.0115 | -0.0104 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 4.753 | 5.129 | 7.78 | 5.028 | 4.887 | 3.756 |
| EBITDA 1 | 0.581 | 0.452 | 1.834 | -1.498 | -2.203 | -2.486 |
| EBIT 1 | 0.549 | 0.412 | 1.728 | -1.621 | -2.353 | -2.666 |
| Net income 1 | 0.295 | 0.072 | 1.325 | -2.443 | -3.406 | -3.061 |
| Net Debt 1 | 8.828 | 9.3 | 7.921 | 11.45 | 13.39 | 14.99 |
| Reference price 2 | 0.0387 | 0.0512 | 0.0350 | 0.0453 | 0.0340 | 0.0250 |
| Nbr of stocks (in thousands) | 295,182 | 295,182 | 295,182 | 295,182 | 295,182 | 295,182 |
| Announcement Date | 4/8/21 A | 4/14/22 A | 4/3/23 A | 4/20/24 A | 4/18/25 A | 4/20/26 A |
1GBP in Million2GBP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 6.51M | |
| 28.61x | 3.96x | 15.3x | 2.55% | 175B | |
| 18.93x | 3.47x | 12.41x | 3.15% | 114B | |
| 16.64x | 0.19x | 12.23x | 0.78% | 57.98B | |
| 35.43x | 3.42x | 11.72x | 2.13% | 50.07B | |
| 28.77x | 7.1x | 18.35x | 1.39% | 50.13B | |
| 34.75x | 6.11x | 19.18x | -.--% | 32.71B | |
| 46x | 1.3x | 12.07x | 0.21% | 30.77B | |
| 43.81x | 7.69x | 27.57x | 0.24% | 26.44B | |
| 55.45x | 7.38x | 23.73x | 0.38% | 23.96B | |
| Average | 34.26x | 4.51x | 16.95x | 1.2% | 56.13B | |
| Weighted average by Cap. | 29.19x | 4.00x | 15.33x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PRM Stock
- Valuation Proteome Sciences plc
Select your edition
All financial news and data tailored to specific country editions
